Share
Share today's newsletter with a colleague
and get credit if they sign up for SmartBrief.
Referral Count:
3
Story being shared
Theravance and GSK submit COPD combo for EU review
GlaxoSmithKline and Theravance filed an application with the European Medicines Agency seeking approval to market Anoro, their once-daily inhaler UMEC/VI, as a maintenance treatment for symptom relief in adult patients with chronic obstructive pulmonary disease. The drug is a combination of vilanterol, a long-acting beta agonist, and umeclidinium bromide, a long-acting muscarinic antagonist.
PharmaTimes online (UK) (1/10)
Or we can send an email on your behalf